CARs and beyond: tailoring macrophage-based cell therapeutics to combat solid malignancies.

Autor:	Abdin SM; Department for Pediatric Pneumology, Allergology and Neonatology, Hannover Medical School, Hannover, Germany.; REBIRTH Research Center for Translational and Regenerative Medicine, Hannover Medical School, Hannover, Germany., Paasch D; REBIRTH Research Center for Translational and Regenerative Medicine, Hannover Medical School, Hannover, Germany.; Institute of Experimental Hematology, Hannover Medical School, Hannover, Germany., Morgan M; REBIRTH Research Center for Translational and Regenerative Medicine, Hannover Medical School, Hannover, Germany.; Institute of Experimental Hematology, Hannover Medical School, Hannover, Germany., Lachmann N; Department for Pediatric Pneumology, Allergology and Neonatology, Hannover Medical School, Hannover, Germany lachmann.nico@mh-hannover.de.; REBIRTH Research Center for Translational and Regenerative Medicine, Hannover Medical School, Hannover, Germany.; RESIST, Cluster of Excellence, Hannover Medical School, Hannover, Germany.; Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH), Member of the German Center for Lung Research (DZL), Hannover, Germany.
Jazyk:	angličtina
Zdroj:	Journal for immunotherapy of cancer [J Immunother Cancer] 2021 Aug; Vol. 9 (8).
DOI:	10.1136/jitc-2021-002741
Abstrakt:	Recent understanding of the role and contribution of immune cells in disease onset and progression has pioneered the field of immunotherapies. Use of genetic engineering to deliver, correct or enhance immune cells has been clinically successful, especially in the field of cancer immunotherapy. Indeed, one of the most attractive approaches is the introduction of chimeric antigen receptors (CARs) to immune cells, such as T cells. Recent studies revealed that adapting this platform for use in macrophages may widen the spectrum of CAR applications for better control of solid tumors and, thus, extend this treatment strategy to more patients with cancer. Given the novel insights into tumor-associated macrophages and new targeting strategies to boost anticancer therapy, this review aims to provide an overview of the current status of the role of macrophages in cancer therapy. The various genetic engineering approaches that can be used to optimize macrophages for use in oncology are discussed, with special attention dedicated to the implication of the CAR platform on macrophages for anticancer therapy. The current clinical status, challenges and future perspective of macrophage-based drugs are highlighted. Competing Interests: Competing interests: NL is author on a pending patent application: 'Stem-cell derived myeloid cells, generation and use thereof', PCT/EP2018/061574. (© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu